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Guest Perspective Dr. Robert L. Brent
HESl News sponsors a series of "GuestPtlspectives" in each
edition as a means of introducing some of the individuals who
devote so much of their time, energy, and talent to the goals and
objectives of HESI. We thank Dr. Robert L. Brent, Distinguished
Professor of Pediatrics, Radiology and Pathology, Thomas
JeffersonUniversib, A.1. duPont Hospital for Children, for
taking the time to introduce us to his background and interests,
and share some of his impressions of HESI.
I first met Alex Malaspina in
1984when he and Dr. Jack Filer
came to Philadelphia to discuss
the possible creation of a new
organization that would be part
of ILSI. Earlier, we had spoken on
the telephone at length about this
new organization. I was looking
forward to our meeting because
of the expected focus of the new
organization on the reproductive
and developmental risks caused
by environmental exposures. I
knew Jack Filer very well. He was
a pediatrician who graduated
from the ~niversitfofRochester
Medical School (my alma mater
as well). His research, teaching,
and administrative activities were
in the field of nutrition. Jack had
recommended me to Alex. We met
on two other occasions at the Stein
Research Center, the developmental and radiation biology institute
that I directed. After these
meetings, we agreed that the new
organization would be devoted to
the entire field of environmental
toxicology, and Alex named the
new organization the Health
and Environmental Science
Institute. The structure of ILSI
was used as the framework for
HESI which meant that the Board
of Trustees would be tripartite,
with corporate representatives,
academic representatives, and
some governmental representation. This was probably the most
important aspect of HESI, because
it provided the checks and balances that markedly reduced the
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idlegation directed toward similar
organizations that primarily
represented the best interests of
industry. A lengthy conflict of
interest document evolved that
was distributed at every meeting
and was frequently flashed on
the screen before each scientific
session. Each board member knew
that there were certain activities
and interactions (for example,
political activity or lobbying) that
were inappropriate for Board
members of a not-for-profit organization.
At the first meeting of HESI, I met
all the members of the Board. I
was impressed. The quality and
accomplishments of the scientists
that represented industry and
academia were outstanding. The
annual scientific meetings were
worth attending because they
were in the forefront of scientific
advances. I personally did not miss
a single scientific session, and I
certainly did not miss the opening
reception and in the early days,
the final sit down banquet.
As HESI matured, so did the
administrative structure of
the organization. The usual
organizational committees were
in place from the start: 1)Bylaws
and Rules Committee, 2) Scientific
Program Committee, 3) Nominating Committee for selecting officer
candidates and board members,
4) meeting site selection, and
5) Finance Committee. As the
organization matured, the goals

were refined and new committees
were formed to attain the goals
that crystalized in the minds of
the officers and members:
6) Membership Development
Committee, 7) Program Strategy
and Stewardship Committee,
8) technical project committees,
and 9) Emerging Issues Steering
Committee.
These latter three committees
were important in that they
encouraged the submission of
new projects that were periodically re-evaluated as to whether
they were accomplishing their
goals and whether their work was
complete. Peer review was an essential feature for all publications,
both in-house and by outside
reviewers. New board members
may be under the impression that
the present structure of HESI was
in place from the beginning of
the organization. That impression
could not be further from-the
truth.
One of the most important
events in HESI's history was the
selection of Dr. Michael Holsapple
as HESI's leader in 2002. He
applied his leadership skills and
his limitless source of energy to
the HESI organization, and it has
worked magic on the enthusiasm
of the staff and board members.
We were all excited by our leader's
election as the vice-president of
the SOT. This honor is a feather
in Michael's cap and an important
indication of HESI's increasing
recognition as a respected and
credible organization.
Most of the members of HESI are
ready and willing to work, write,
and function on committees.
Like every volunteer organization, we have a few individuals
who are difficult to motivate;
however, most of the members are
See GUEST PERSPECTIVE, page 7

GUEST PERSPECTIVE, from page 6

enthusiastic about meeting their responsibilities and the
goals of the organization. The recent Mapping exercise
initiated by Dr. Lewis Smith consumed over three years
of staff and scientists' time. The manuscript describing
this exercise is complete and was accepted for publication
in Critical Reviews in Toxicology. I believe it will be an
important HESI publication that will put HESI on the
map (pun intended).
I remember that when I was elected for a three-year term
to the Board, the rules were that you could be re-elected,
but that was not a guarantee. As the years went by, I
noticed that many of the colleagues who were elected
with me in the early years were gone, and this happened
again and again. I said to my wife, "I wonder if they
have forgotten about me?" I believe I was elected five
times, and I am most appreciative of the opportunities
and education in toxicology that I received from HESI's
activities. It has been a wonderful experience and I will
continue to wish HESI future successes and important
accomplishments.It is a very important international
organization, and of which the membership should be
very proud.

HESI Committee to Submit
a Biomarker Qualification
Package to FDA
The Nephrotoxicity Working Group of the
HESI Biomarkers Technical Committee will
submit a voluntary biomarker qualification
data package (VXDS) to the FDA at the end of
April 2008. The focus of the submission will
be the analytical and biological validation
study data generated by the working group
over the last three years on the markers RPA1,clusterin, and alpha- and mu-GST. These
data will be evaluated by FDA reviewers to
assess their utility for specific preclinical safety
applications.
For more information, contact Syril D. Pettit,
MEM, Senior Scientific Project Manager, at
spettit@hesiglobal.org.

a greater HESI presence in Japan
emerged as strong recommendations from the session.

HESI Goes to Tokyo
On February 20,2008, HESI led a
well-attended outreach meeting
at the Tokyo Opera City building
in Tokyo, Japan. More than 40
Japan-based scientists from the
pharmaceutical and chemical
sectors, academia, and government attended the meeting. The
session provided an important
opportunity to bridge geographic
and time boundaries, and have
valuable face-to-face discussions
with our Japanese colleagues.
Dr. Michael Holsapple (HESI
Executive Director), Dr. Marc
Bonnefoi (sanofi-aventisand
HESI Vice-President), and
Ms. Syril Pettit (HESI Senior
Scientific Program Manager)
represented HESI at the session.
The one-day program included
an overview of the HESI organization and mission, as well as
presentations on the biomarkers,
genomics, nanotechnology, protein allergenicity, and

Attendees at the February 2008 HESI
Outreach Meeting in Tokyo, Japan. (Photo
by S. Pettit)

in vitro genotoxicity committees.
Participants were offered opportunities to provide written
and verbal feedback on challenges
and benefits of working with the
HESI organization. The need for
more frequent HESI activities and

Downtown Tolyo. IDhoto by %.Pettit)

Drs. Makoto Hiyashi (Japan National
Institute of Health Sciences), Molsapple,
and Bonnefoi (left to right) discuss in vitro
genotoxicity testing paradigms during a
meeting break. (Photo by S. Pettit)

HESI looks forward to returning
to Japan several times in the
next 18 months with sessions at
the Japan Society of Toxicology
meeting, Japan Environmental
Mutagen Society, and other
scientific forums.
Special thanks to sanofi-aventis in
Tokyo for assisting with logistical
support for the meeting.
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